Literature DB >> 19634052

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.

Ingrid M E Desar1, H Jorn Bovenschen, Anja J N H Timmer-Bonte, Mireille V Cantarini, Winette T A Van Der Graaf, Michelle M Van Rossum, Carla M L Van Herpen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19634052     DOI： 10.3109/02841860903104152

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  3 in total

1.  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Authors:  Yevgeniy Balagula; Katherine Barth Huston; Klaus J Busam; Mario E Lacouture; Paul B Chapman; Patricia L Myskowski
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

2.  Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Authors:  John M Kirkwood; Lars Bastholt; Caroline Robert; Jeff Sosman; James Larkin; Peter Hersey; Mark Middleton; Mireille Cantarini; Victoria Zazulina; Karin Kemsley; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2011-11-02       Impact factor: 12.531

Review 3.  The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis.

Authors:  Chen Peng; Lei Jie-Xin
Journal:  Eur J Hosp Pharm       Date:  2020-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.